ArticleInfectious diseases and therapy2026

Immunogenicity, Tolerability, and Safety of BA.1-Adapted BNT162b2 Vaccine in 18- to 55-Year-Olds Previously Vaccinated with BNT162b2 or Who Were COVID-19 Vaccine-Naive.

David Fitz-Patrick et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.